Clinical trial
A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT02600897 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- March 24, 2016
- Completion date
- December 15, 2021
- Enrollment
- 114 (actual)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.
relapsed or refractory follicular lymphoma, relapsed or refractory diffuse large b-cell lymphoma